Groundbreaking Colon Cancer Screening Tests Now Available!
As the third most commonly diagnosed cancer and the third leading cause of cancer related deaths, each year an estimated 50 000 deaths occur worldwide from colon cancer. Currently, in 2014 alone, there have been over 136 830 people diagnosed with colon cancer worldwide that we know of. With symptoms that range from abdominal distension and pain, unexplained nausea or vomiting, considerable weight loss and noticeable change in bowel movements, to narrow stools and rectal pain – many deaths can be prevented with early detection and treatment by routine colon cancer screening of asymptomatic people.
The Latest Scientific Developments in the Detection of Colon Cancer
Fortunately, there have been remarkable progressive developments in the detection of early colon cancer by means of new, state-of-the-art colon cancer screening procedures. Gone are the days of the standard colonoscopy or the faecal occult blood test (FOBT), which only gives information on bleeding malignant tumours and growths.
Revolutionary, pioneering studies and investigations done by researchers at the University of Giessen, in Germany, established that not all malignant tumours leak blood, but what they do leak is a specific chemical known as Tumour M2-PK into the bowel, and as a biotechnology company at the forefront of medical science, ScheBo Biotech AG used these groundbreaking findings to cultivate an Enzyme-Linked Immunosorbent Assay (ELISA) test.
With the use of a single pea-sized stool sample, the M2-PK test is not only able to immediately detect malignancy of any degree in the colon, but it also indicates immediate tumour and growth activity in the colon. Combining exceptional precision with a high degree of specificity of 81% independent of occult blood, the M2-PK ELISA test is now a vital requirement for colon cancer screening in patients of all ages. Having made remarkable progress in medical science with the Faecal M2-PK ELISA test, ScheBo Biotech AG has also developed a follow-up colon cancer screening M2-PK serum for the post-treatment.
An established internationally celebrated company at the forefront of advanced medical science research, ScheBo Biotech AG has academic alliances with several universities and university hospitals throughout Europe, Israel, Canada and the United States of America. In medical science diagnostics, not only is ScheBo Biotech AG recognised for its Faecal M2-PK ELISA colon cancer screening test and M2-PK serum test for the post colon cancer screening treatment, but ScheBo Biotech AG has also made remarkable development and advancements in its Pancreatic Elastase 1 Stool Test (faecal elastase), which is rapidly becoming recognised as the “gold standard” of non-invasive pancreatic function tests.
About IEPSA
Formed in 1980, we at IEPSA are currently South Africa’s leading laboratory equipment supplier, and also the sole agent for some of the leading diagnostic product companies at the forefront of global medical science, such as ScheBo Biotech AG, Kreatech, MP Biomedicals, Advanced Instruments & Fiske, Chart Biomedical, Irvine Scientific, Planer Products, Cryo Bio System, Neogen, CDR systems, MTG Technology and Analox Sensor Technology.
As a laboratory equipment supplier with an interest in medical science, we can offer you a much more accurate, effective and non-invasive way of colon cancer screening. Working closely with a team of highly trained and skilled representatives who are experts in their fields, we keep up with all of the latest, most progressive products available in the global medical market. To learn more about our equipment and products, contact us today!
